Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sutro Biopharma Inc.

This article was originally published in Start Up

Executive Summary

Scientists have long tinkered with cell-free methods of protein synthesis, but turning their lab bench discoveries into commercially actionable ones is usually a tedious affair that ultimately requires the return to traditional cell line development. Sutro Biopharma claims to have developed a speedy cell-free way of producing proteins that can swiftly shift from laboratory to commercial scale. Rather than packaging the process for widespread use by researchers, Sutro is seeking to collaborate with partners intent on creating biopharmaceuticals--ideally, companies interested in high-throughput protein engineering.

You may also be interested in...



Start-Up Previews (06/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Set Sights on Flu," features profiles of Alios BioPharma, Immune Targeting Systems, Marinomed Biotechnologie and Vivaldi Biosciences. Plus these Start-Ups Across Health Care: CardiAQ Valve Technologies, NKT THerapeutics, SPOC Inc.,and Sutro Biopharma.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel